Dyne Therapeutics, Inc. DYN R2KR3KPHARMA
Company Overview
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.33.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +27.61% |
| 6 Months: | -14.46% |
| 3 Months: | -39.06% |
| 1 Month: | -5.39% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)41.48 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 41.7% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | DYN Dyne Therapeutics, Inc. R2KR3KPHARMA | 15.62 | -4.73 | $2.92B | 0.00% | -41.20% | -81.57% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | - | - | -3.63M | -7.85M | -8.68M | -13.52M | -25.13M | -30.16M | -42.77M | -35.78M | -52.76M | -42.28M | -45.46M | -66.74M | -62.27M | -69.16M | -71.96M | -105.57M | -122.37M | -115.79M | -113.89M | -125.28M | -181.66M |
| Net Income | -2.09M | -1.50M | -5.87M | -7.89M | -8.98M | -13.92M | -24.97M | -29.95M | -42.58M | -35.58M | -52.30M | -41.38M | -44.19M | -64.90M | -60.21M | -65.65M | -65.10M | -97.12M | -115.36M | -110.86M | -108.04M | -120.85M | -178.56M |
| Diluted EPS | - | - | - | - | - | - | - | -0.58 | -0.83 | -0.69 | -1.01 | -0.80 | -0.78 | -1.08 | -0.99 | -0.81 | -0.70 | -0.96 | -1.05 | -0.97 | -0.76 | -0.73 | -1.08 |
| R&D Expense | - | - | 2.98M | 6.09M | 7.33M | 9.68M | 18.62M | 23.87M | 36.51M | 28.24M | 46.66M | 34.67M | 37.54M | 59.13M | 55.25M | 44.54M | 62.26M | 92.80M | 106.45M | 99.24M | 97.22M | 100.89M | 152.17M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Income | -13.83M | -58.65M | -150.03M | -170.96M | -242.16M | -343.89M | -468.18M |
| Net Income | -14.86M | -59.44M | -149.29M | -168.10M | -235.94M | -317.42M | -446.21M |
| Diluted EPS | - | - | -2.93 | -3.23 | -3.95 | -3.37 | -3.47 |
| R&D Expense | 11.04M | 45.20M | 121.31M | 142.76M | 210.76M | 281.41M | 398.33M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 16.44M | 353.33M | 425.66M | 306.32M | 165.08M | 691.23M | 1.19B |
| Total Equity | -4.88M | 14.04M | 342.37M | 368.20M | 252.36M | 91.29M | 629.84M | 972.13M |
| Cash & Equivalents | - | 14.63M | 300.85M | 200.82M | 172.15M | 121.63M | 435.45M | 893.37M |
| Long Term Debt | - | - | - | - | - | - | 0 | 148.92M |
| Total Liabilities | - | 2.40M | 10.97M | 57.47M | 53.96M | 73.79M | 61.40M | 214.83M |
| Current Liabilities | - | 2.36M | 10.97M | 28.72M | 28.09M | 51.09M | 42.26M | 50.62M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -11.83M | -46.51M | -119.56M | -153.65M | -188.16M | -292.37M | -403.21M |
| Investing Cash Flow | -1.65M | -45.66M | -137.89M | 87.20M | 83.31M | -204.08M | -28.75M |
| Financing Cash Flow | 19.99M | 380.69M | 157.82M | 37.39M | 54.32M | 809.89M | 890.31M |
| Capital Expenditure | -1.65M | -1.16M | -3.62M | -3.07M | -729.00K | -2.38M | -1.92M |
| Free Cash Flow | -13.48M | -47.67M | -123.18M | -156.71M | -188.89M | -294.75M | -405.13M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - |
| ROE % | -105.9% | -17.4% | -40.5% | -66.6% | -258.4% | -50.4% | -45.9% |
| ROCE % | -98.2% | -17.1% | -37.8% | -61.4% | -212.4% | -53.0% | -41.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | T. Rowe Price Investment Management, Inc. | 16.55% | 30.91M | $514.38M |
| 2 | Blackrock Inc. | 6.64% | 12.40M | $206.41M |
| 3 | Jupiter Topco LLC | 6.42% | 12.00M | $199.64M |
| 4 | FMR, LLC | 6.00% | 11.21M | $186.48M |
| 5 | State Street Corporation | 3.99% | 7.46M | $124.11M |
| 6 | Orbis Allan Gray Ltd | 3.75% | 7.01M | $116.59M |
| 7 | Atlas Venture Life Science Advisors, LLC | 3.64% | 6.80M | $113.15M |
| 8 | Vanguard Capital Management LLC | 3.38% | 6.31M | $105.01M |
| 9 | TCG Crossover Management, LLC | 2.47% | 4.62M | $76.80M |
| 10 | Vanguard Portfolio Management LLC | 2.17% | 4.05M | $67.37M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for DYN
Dyne Therapeutics, Inc. Estimates – NASDAQ:DYN - TradingView
<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTE1EaS1XaHdObFI3ekI4SWJmRWM2OUVIM2lKMG54Umo0Zkp5dEZzeGMyUXk3WXV2R2loZm5hWXZsTVp6WWhfbGNEMkN5WEl5dlJrc2IzSTZWVVFTczUxRDdNVWFHakpTUTRHcTdWNVJJQ2JGNElIQUxB?oc=5" target="_blank">Dyne Th…
DYN Mar 2027 29.000 call (DYN270319C00029000) Stock Historical Prices & Data - Yahoo Finance - Yahoo! Finance Canada
<a href="https://news.google.com/rss/articles/CBMib0FVX3lxTE5sSUFjbnFydVU3Y0hCd3NhODJMVXd5UkE0Ulo3eDlON2RYVzdJWnhXQ005ZzZhNU9QUWE1b2ttQktoR28wdEthY0poMk93SGJUQTRfU3hlZTJTWDQ1SE9XbkVKM0ZlQ2s1R3V4VTUwMA?oc=5" target="_blank">DYN Mar 2027 29.0…
Dyne: Recent Price Drop On Rival's DM1 Data Creates (Risky) 'Buy The Dip' Scenario (DYN) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxONUtuWXVwdG9pclo5TUI4UzFRMUU4S0NrSDluSkVNRjg3VkVjcVpVeWo2Y2I5VVJXT2d0eTAxa0tsUHBLdDJSMU1yUWxsUW5ORm9kRVd3SVdQR2dVSGlSdHM5XzNlcmlwWkt2b215cnBSRmM1LUlHcHpiLWZfZ0k2cXU1VjhrQXBYZ3M3VV…
A 12,000-share option goes to Dyne Therapeutics (DYN) CMO Douglas Kerr alongside a stock award. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxQQ1AtZXJXQnZnSzRidC1mNkNKSzRzMlhuVWx1M1lJSFJmSU5pdEFHMUVrTmlOT0s2bW9KNFptY1JnR0Zxck4yeU1uZFg3SkVpRGs5V2FUbkplMGxsSll2eXdaeVpWVVh1U2thVGxReWJxZ3RnN1Jrc2JmOHFURER6S1BZVkgtaFBaZGZXSW…
DYN Nov 2026 18.000 put (DYN261120P00018000) Interactive Stock Chart - Yahoo! Finance Canada
<a href="https://news.google.com/rss/articles/CBMibEFVX3lxTE5QT0w4SUdrUzZGX3E2cm9NbEZ5RGNubXdUd2hhOE1hQ05pczV0emhMWVd5bHJtcG8wNUJqOGJwc2tOejhyam1UNW1hY1Y4RnB1LXpwRXBWQ3pTaks0R2xzMXpYbmJMQmotQTBvMw?oc=5" target="_blank">DYN Nov 2026 18.000 p…
Dyne Therapeutics Remains A Buy Even As Novartis Trial Failure Hits DM1 Class (NASDAQ:DYN) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxPeFMybjh1NHh6cDVBanVTWnJkRVJUMTRTcklsTEl0NXVDc2U5b1ljQy1DRzBFTHFfMzFfUFJ3clROazRxaWRkMXRSSlgwbXNGeTBfQW5DUTc3ZktzMXdwXzdvVmtxWUR5ZlRTWVc3NHljSkdfdlRVVDJ5OXRJTDB4d3N3Vkh4STR1Rm5NeH…
DYN — Frequently Asked Questions
What is the current share price of Dyne Therapeutics, Inc. (DYN)?
As of 2026-10-23 16:27 PDT, Dyne Therapeutics, Inc. (DYN) trades at $15.62 on NasdaqGS. Its 52-week range is $11.97 to $26.78.
What is the market capitalisation of DYN?
Dyne Therapeutics, Inc. (DYN) has a market capitalisation of $2.92B on NasdaqGS.
What is the P/E ratio of DYN?
DYN trades at a trailing price-to-earnings (P/E) ratio of -4.73. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 3.93.
What is the return on equity (ROE) of DYN?
DYN has a return on equity (ROE) of -81.57%. Its return on capital employed (ROCE) is -41.20%.
Is DYN a good stock to buy?
This page provides a data-driven analysis of Dyne Therapeutics, Inc. (DYN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.